Cytokinetics (CYTK)

May 13, 2025, 4:06 PM EDT - 6 hours ago

Cytokinetics: PDUFA Date Extension For Aficamten Is Not At All Earth Shattering

May 13, 2025, 10:00 AM EDT - 12 hours ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Investors to Learn More About the Investigation

May 13, 2025, 7:45 AM EDT - 14 hours ago

Cytokinetics' heart disease drug meets main goal in late-stage study

May 13, 2025, 7:30 AM EDT - 14 hours ago

Cytokinetics Announces Positive Topline Results From MAPLE-HCM

May 12, 2025, 10:00 AM EDT - 1 day ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

May 11, 2025, 10:00 AM EDT - 2 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect

May 9, 2025, 10:00 AM EDT - 4 days ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Stockholders to Connect

May 8, 2025, 4:00 PM EDT - 5 days ago

Cytokinetics Announces Four Upcoming Presentations at the European Society Of Cardiology Heart Failure 2025 Congress

May 8, 2025, 10:00 AM EDT - 5 days ago

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 7, 2025, 4:00 PM EDT - 6 days ago

Cytokinetics to Hold Annual Meeting of Stockholders

May 7, 2025, 11:29 AM EDT - 6 days ago

Cytokinetics: Strong Buy As FDA's 3-Month Delay Doesn't Derail Aficamten's Approval Outlook

May 7, 2025, 10:00 AM EDT - 6 days ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Cytokinetics, Incorporated (CYTK) and Encourages Stockholders to Learn More About the Investigation

May 7, 2025, 1:56 AM EDT - 6 days ago

Cytokinetics, Incorporated (CYTK) Q1 2025 Earnings Call Transcript

May 6, 2025, 6:12 PM EDT - 7 days ago

CYTK Investors Have Opportunity to Join Cytokinetics, Incorporated Fraud Investigation with the Schall Law Firm

May 6, 2025, 4:00 PM EDT - 7 days ago

Cytokinetics Reports First Quarter 2025 Financial Results and Provides Business Update

May 6, 2025, 10:00 AM EDT - 7 days ago

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Investors to Inquire about Securities Investigation

May 5, 2025, 1:45 PM EDT - 8 days ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Cytokinetics, Incorporated (CYTK) And Encourages Investors to Reach Out

May 2, 2025, 3:37 PM EDT - 11 days ago

FDA Pushes Potential Approval For Cytokinetics' Experimental Heart Drug By Three Months

May 2, 2025, 11:45 AM EDT - 11 days ago

Cytokinetics, Incorporated Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CYTK

May 1, 2025, 4:15 PM EDT - 12 days ago

Cytokinetics Announces New PDUFA Date for Aficamten in Obstructive Hypertrophic Cardiomyopathy

Apr 30, 2025, 4:00 PM EDT - 13 days ago

Cytokinetics to Participate in May Investor Conferences

Apr 22, 2025, 4:00 PM EDT - 21 days ago

Cytokinetics to Announce First Quarter Results on May 6, 2025

Apr 17, 2025, 4:00 PM EDT - 26 days ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 31, 2025, 4:00 PM EDT - 6 weeks ago

Cytokinetics to Participate in the 24th Annual Needham Virtual Healthcare Conference

Mar 20, 2025, 7:30 AM EDT - 7 weeks ago

Cytokinetics Announces Launch of EARTH-HCM, a Public Health Education Tool for the Hypertrophic Cardiomyopathy Community

Mar 17, 2025, 8:00 AM EDT - 2 months ago

Cytokinetics Announces Five Presentations at the American College of Cardiology Annual Scientific Session & Expo

Mar 16, 2025, 10:22 AM EDT - 2 months ago

Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten

Mar 3, 2025, 4:00 PM EST - 2 months ago

Cytokinetics to Participate in March Investor Conferences

Feb 27, 2025, 7:49 PM EST - 2 months ago

Cytokinetics, Incorporated (CYTK) Q4 2024 Earnings Call Transcript

Feb 27, 2025, 4:00 PM EST - 2 months ago

Cytokinetics Reports Fourth Quarter 2024 Financial Results and Provides Business Update

Feb 18, 2025, 10:20 AM EST - 3 months ago

20 stocks of companies expected to put up numbers to back investors' new ‘growth mindset'

ARWR AUB CRK EXE KRYS MARA MP

Feb 13, 2025, 4:00 PM EST - 3 months ago

Cytokinetics to Announce Fourth Quarter Results on February 27, 2025

Feb 11, 2025, 7:30 AM EST - 3 months ago

Cytokinetics Names Robert E. Landry to Board of Directors

Feb 5, 2025, 4:00 PM EST - 3 months ago

Cytokinetics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 30, 2025, 12:22 PM EST - 3 months ago

Kuehn Law Encourages Investors of Cytokinetics, Inc. to Contact Law Firm

Jan 30, 2025, 7:30 AM EST - 3 months ago

Cytokinetics Announces Recipients of Its Seventh Annual Communications Grant Program

Jan 22, 2025, 3:43 PM EST - 3 months ago

Cytokinetics Heart Drug's Future Sparks Optimism Despite M&A Hurdles and Royalty Deal Concerns: Analyst

Jan 21, 2025, 7:30 AM EST - 4 months ago

Cytokinetics Announces Start of AMBER-HFpEF, a Phase 2 Clinical Trial of CK-586 in Patients With Symptomatic Heart Failure With Preserved Ejection Fraction

Jan 13, 2025, 7:30 AM EST - 4 months ago

Cytokinetics Announces 2025 Corporate Milestones and Vision 2030

Jan 6, 2025, 4:00 PM EST - 4 months ago

Cytokinetics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 3, 2025, 4:00 PM EST - 4 months ago

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)